www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024

« Back

Share Buy-Back in ALK - week 5

January 29, 2013

PDF Version

Supporting Materials:
AT_W5_UK_29012013.pdf

 

Copenhagen, 2013-01-29 08:56 CET (GLOBE NEWSWIRE) --  

On 14 May 2012, ALK-Abelló A/S ("ALK") initiated a share buy-back programme, cf. company announcement No. 14/2012. According to the programme, ALK will in the period from 15 May 2012 to 4 February 2013 purchase own shares for a maximum amount of DKK 75 million and no more than 200,000 shares corresponding to 2.0% of the current share capital of ALK. The share buy-back programme is initiated and structured in compliance with the EU Commission Regulation No. 2273/2003 of 22 December 2003 and thus ALK will publish the accumulated share buy-back under the programme every week.

The following transactions have been made under the programme:

 No of shares bought backAverage transaction priceAmount (DKK)
Accumulated, last announcement
105,087
 

 
 
39,465,113
22 January 2013 450 410.80 184,860
23 January 2013 301 410.52 123,568
24 January 2013 727 410.28 298,274
25 January 2013000.00 0
28 January 2013 600 412.00 247,200
Accumulated under the programme
107,165
 
376.23
 
40,319,015

As of today, ALK's total holding of own shares is 464,882 shares of a nominal value of DKK 10, corresponding to 4.6% of the total number of issued shares of 10,128,360. 

ALK-Abelló A/S
 

Jens Bager
President and CEO

 

For further information please contact:
Per Plotnikof, Investor Relations Director, tel. +45 4574 7527

 

  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved